Table 1.
Patient characteristics
| Variables | Group 1 | Group 2 | Group 3 | p value |
|---|---|---|---|---|
| N | 133 | 43 | 170 | |
| Age (yrs) | 75±7.4a,b | 67±8.1 | 65±12.0 | <0.0001 |
| Weight (kg) | 70.4±10.8 | 71.5±11.6 | 72.8±14.4 | 0.4 |
| Height (cm) | 166.5±6.8b | 169.4±6.8 | 169.6±7.3 | 0.006 |
| BMI (kg/m2) | 25.4±3.9 | 25.0±3.9 | 25.2±4.2 | 0.8 |
| T score | -1.6±1.5a,b | -0.9±1.1 | -0.7±1.4 | <0.0001* |
| Normal Bone density† | 40 (30) | 23 (55) | 95 (58) | 158 (46) |
| Osteopenia† | 56 (41) | 18 (40) | 59 (33) | 133 (37) |
| Osteoporosis† | 37 (29) | 2 (5) | 16 (9) | 56 (17) |
Values are mean±s.d.
†values are counts (%).
Group 1- prostate cancer patients receiving androgen deprivation therapy.
Group 2- prostate cancer patients, hormonally naiive.
Group 3- non prostate cancer patients; hormonally naiive.
BMI- Body Mass Index.
p value comparison of means by analysis of variance (ANOVA) with post hoc comparisons by Scheffe.
a- Group 1 vs Group 2: p<0.005.
b- Group 1 vs Group 3: p<0.005.
c- Group 2 vs Group 3: p<0.005.
* p value comparison of ranks by Kruskal Wallis procedure with post hoc comparisons by Wilcoxon test.
a- Group 1 vs Group 2: p<0.005.
b- Group 1 vs Group 3: p<0.005.
c- Group 2 vs Group 3: p<0.005.